Guadalupe Canahuate

The University of Iowa
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Purpose Sleep-related symptom prevalence is not well-characterized and likely under-recognized in head and neck cancer. We investigated longitudinal symptom severity trajectory, prevalence of moderate/severe symptoms, and association between severe sleep-related patient-reported symptoms and oncologic endpoints in oropharyngeal cancer (OPC) patients receiving radiotherapy (RT). Methods A longitudinal cohort of 372 patients with OPC treated with curative-intent RT with/without chemotherapy at a single-site tertiary center was queried at RT start, end of RT, and six months post-RT. All completed baseline MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) at start of RT. Sleep-related symptom items included “fatigue”, “disturbed sleep”, and “drowsiness” (mild, moderate, severe). Clinical data were collected, and overall survival (OS) was evaluated using Kaplan-Meier/log-rank tests and multivariable Cox proportional hazards models with covariate adjustment. Results Severe fatigue, disturbed sleep, and drowsiness were infrequent at baseline and at RT start, but peaked at RT end (26%, 15% and 18%) and returned to near-baseline prevalence by six months after RT (6%, 4%, 2%). In Cox proportional hazard models, severe longitudinal fatigue (HR 5.05, 95% CI 1.25-17.07, p = 0.013), sleep (HR 3.86, 95% CI 1.23 to 10.16, p = 0.0104), and drowsiness burden (HR 8.24, 95% CI 1.22 to 32.62, p = 0.008) were all independently associated with worse OS. Additionally, severe fatigue (HR = 3.58, 95% CI: 1.09 to 10.11, p = 0.0375), sleep disturbance (HR 5.08, 95% CI 1.60-13.51, p = 0.0081), and drowsiness (HR=7.76, 95% CI 1.45-33.47, p=0.0193) reported at RT start were also independently associated with significantly worse OS. Aside from age, severe average daily symptom scores, and severe symptoms reported at RT start, were independently associated with worse OS. Conclusion Severe sleep related symptoms were uncommon at baseline or RT start, but a substantial proportion of OPC patients experienced clinically meaningful sleep disturbances by the end of RT. At an average follow up of 84 months, severe longitudinal fatigue, sleep, and drowsiness burden were all independently associated with worse OS in OPC. Severe fatigue, drowsiness and sleep disturbance reported at RT start were also independently associated with worse OS. Assessment of sleep disturbances along with potential physiologic correlates are an important part of comprehensive care.

Year:

2025

Osteoradionecrosis of the jaw (ORNJ) is a radiation-induced late toxicity that can dramatically decrease patients’ quality of life. Recent increases in survival rates of head and neck cancers associated with human papillomavirus (HPV) infection have resulted in a higher frequency of radiation-induced toxicities, particularly ORNJ. Recent work with Normal Tissue Complication Probability (NTCP) models and a Weibull Accelerated Failure Time (WAFT) model have further developed our understanding of ORNJ clinical/dosimetric risk factors and longitudinal features, respectively. In this data descriptor, 1129 head and neck cancer (HNC) patients received curative intent radiotherapy (RT) at MD Anderson Cancer Center and were follow-up with clinical and radiological assessments at 3-6, 12, 18, 24 months, and then annually following the conclusion of RT for development of ORNJ. This data, in addition to the patients’ demographic, supplementary clinical, and dosimetric information was recorded in a comma-separated value file embedded within this data descriptor. This large, longitudinal dataset is a significant resource for further systematic analysis of post-RT normal tissue outcomes in HNC.

Year:

2025

Background Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has important implications to monitor oral health in head and neck cancer (HNC) long-term survivors. Methods Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Anderson Cancer Center. ORNJ was diagnosed in 198 patients (18%). A multivariable logistic regression analysis with forward stepwise variable selection identified significant predictors for ORNJ. These predictors were then used to train a Weibull Accelerated Failure Time (AFT) model, which was externally validated using an independent cohort of 265 patients (92 ORNJ cases and 173 controls) treated at Guy’s and St. Thomas’ Hospitals. Findings Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to a 27% faster (ATR 0·73, p=0·13) onset of ORNJ; male patients experienced a 38% shorter time to ORNJ (ATR 0·62, p = 0·11). The model demonstrated strong internal calibration (integrated Brier score of 0·133, D-calibration p-value 0.998) and optimal discrimination at 72 months (Harrell’s C-index of 0·72). The model also showed good generalization to the independent cohort, despite a slight drop in performance. Interpretation This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the probability of a late effect (ORNJ), but the conditional risk during survivorship. Funding This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation.

Year:

2024

Year:

2023

Collaborators (22)

Anna Lee

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Steven Frank

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lisanne van Dijk

Associate professor & Technical physician

University Medical Center Groningen

NETHERLANDS
View details

Katherine Hutcheson

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Natalie West

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Saadia Faiz

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jack Phan

Physician/Associate Professor

MD Anderson Cancer Center

UNITED STATES
View details

Seyedmohammadhossein Hosseinian

Assistant Professor

North Carolina State University

UNITED STATES
View details

Michael T. Spiotto

-

UNITED STATES
View details

Vlad Sandulache

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Stephen Lai

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Amy Moreno

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew Schaefer

Professor

Rice University

UNITED STATES
View details

Teresa Guerrero Urbano

Adjunct Reader

King's College London

UNITED KINGDOM
View details

Mark Chambers

Professor & Deputy Chair/Medical Director, Section of Oral Oncology and Maxillofacial Prosthodontics

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jillian Rigert

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Melissa Chen

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

G.E. Marai

-

UNITED STATES
View details

Mohamed Naser

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Abdallah Mohamed

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Zaphanlene Kaffey

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Clifton D Fuller

Professor (Tenured)

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details